Vaccine (Peptide vaccine) · Immune activation, directed at WT1 · developed by Sellas Life Sciences Group
Galinpepimut-S is a peptide cancer vaccine comprised of four WT1-derived peptide chains designed to elicit CD4-positive and CD8-positive T-cell responses against WT1-expressing tumor cells. It is studied in acute myeloid leukemia and malignant pleural mesothelioma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04229979 | Phase 3 | Acute Myeloid Leukemia | Active not recruiting | SLS |
| NCT01265433 | Phase 2 | Malignant Pleural Mesothelioma | Completed | SLS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaMalignant Pleural Mesothelioma
Updated Oct 3, 2026. Something wrong or missing? Report it on the SLS page.
See SLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SLS catalysts and pipeline →